linezolid and tapentadol hydrochloride: label evidence and limits

The NUCYNTA label names linezolid as a monoamine oxidase inhibitor. It warns of serotonin syndrome or opioid toxicity with MAOI interactions and contraindicates NUCYNTA during MAOI use or within the preceding 14 days.

Which products this evidence covers

NUCYNTA oral tapentadol tablets.

What this finding does and does not establish

The label’s contraindication supports a strong warning for the specified product. Patients should ask their prescriber or pharmacist about their medicines rather than adjust treatment themselves.

Supporting label passage

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Read the product label on DailyMed. Section: 7 Drug Interactions — Monoamine Oxidase Inhibitors. Compared label version 7, dated 2025-12-30.

How this brief was prepared

This brief uses an AI-assisted source comparison dated 2026-10-16. The label version and supporting passage were checked again on 2026-10-28. Independent clinical review has not been recorded. The comparison does not validate CDI's severity category or determine individual treatment.

Discuss your exact medicines with your pharmacist

Ask whether the cited formulation and route apply to your products and circumstances. Confirm medication decisions with your pharmacist or prescriber before changing treatment.

Check your medication list with CDI.